Investing.com - RVL Pharmaceuticals (NASDAQ: RVLP) reported first quarter EPS of $-0.120, in line with the analyst estimate of $-0.120. Revenue for the quarter came in at $8.8M versus the consensus estimate of $13.79M.
RVL Pharmaceuticals's stock price closed at $0.850. It is down -27.970% in the last 3 months and down -38.850% in the last 12 months.
RVL Pharmaceuticals saw positive EPS revisions and negative EPS revisions in the last 90 days. See RVL Pharmaceuticals's stock price’s past reactions to earnings here.
According to InvestingPro, RVL Pharmaceuticals's Financial Health score is "weak performance".
Check out RVL Pharmaceuticals's recent earnings performance, and RVL Pharmaceuticals's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar